

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



February 5, 2026  
Fuji Pharma Co., Ltd.

## **Notice Regarding Loss on Valuation of Securities for the First Quarter of the Fiscal Year ending September 2026**

Fuji Pharma Co., Ltd. (hereinafter referred to as the "Company") hereby announces that in the first quarter of the fiscal year ending September 2026, the Company recorded impairment losses on Japanese GAAP-based available-for-sale securities (other securities) held by the Company, the market value of which had fallen significantly, resulting in the need to record a loss on valuation of securities.

### **1. Loss on valuation of securities for the first quarter of the fiscal year ending September 2026**

Total loss on valuation of securities for the first quarter of the fiscal year ending September 2026 (October 1, 2025 to December 31, 2025): 2,457million yen

※The above loss on valuation of securities was incurred due to a significant decline in the share price of Alvotech Holdings S.A. (listed on NASDAQ), a global licensor for the biosimilars business, which is positioned as part of our growth strategy.

※The revaluation method for securities on a quarterly basis is the wash-up method, and the loss on valuation of securities will fluctuate depending on the share price at the end of the second and third quarters of the fiscal year ending September 2026 or the end of the fiscal year ending September 2026.

※ The Company's fiscal year-end is September 30.

### **2. Future Outlook, etc.**

Please refer to the "Notice Regarding Revision of Earnings Forecast" released today for the impact on consolidated financial results for the first half and full year of the fiscal year ending September 30, 2026.

### **For further information, contact**

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

[fsk\\_ir@fujipharma.jp](mailto:fsk_ir@fujipharma.jp)